Nevertheless, the possibility to quantify with Q‐PCR the WT1 gene, which is overexpressed in up to 80–90% of AML cases, overcomes this limit and offers the opportunity to monitor a MRD marker in the great majority of patients, although its specificity in detecting the leukemic clone remains controversial. The gene discussed is WT1; the disease is acute myeloid leukemia.